Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 26.
doi: 10.1002/acn3.70167. Online ahead of print.

Durability of Response to B-Cell Maturation Antigen-Directed mRNA Cell Therapy in Myasthenia Gravis

Nizar Chahin  1 , Gregory Sahagian  2 , Marc H Feinberg  3 , C Andrew Stewart  4 , Christopher M Jewell  4 , Metin Kurtoglu  4 , Miloš D Miljković  4 , Tuan Vu  5 , Tahseen Mozaffar  6 , James F Howard Jr  7 ; MG‐001 Study Group
Affiliations

Durability of Response to B-Cell Maturation Antigen-Directed mRNA Cell Therapy in Myasthenia Gravis

Nizar Chahin et al. Ann Clin Transl Neurol. .

Abstract

Objective: We report the 12-month follow-up outcomes from a Phase 2 clinical trial (NCT04146051) evaluating Descartes-08, a BCMA-directed RNA chimeric antigen receptor T-cell (rCAR-T) therapy for refractory generalized myasthenia gravis (MG). These findings provide insight into the potential applicability of BCMA-targeted rCAR-T therapy for antibody-mediated autoimmune diseases.

Methods: In the Phase 2a part of the study, Descartes-08 was administered at 52.5 × 106 CAR+ cells/kg per infusion with varying dosing frequencies as an outpatient treatment and without lymphodepletion chemotherapy. A subset of participants received Descartes-08 as six weekly infusions and were followed long term with assessments conducted at 2, 3, 6, 9, and 12 months.

Results: All seven participants who received six weekly infusions of Descartes-08 exhibited clinically meaningful improvement in common MG severity scales (MG Composite, MG Activities of Daily Living, Quantitative MG scores, and Quality of Life 15-revised) at Month 3 without significant toxicity. At Month 9 follow-up, all participants continued to experience marked clinically meaningful improvements. Five out of seven participants maintained the response at Month 12. A third participant experienced a relapse approximately 6 months after completing on-study follow-up. All three participants who experienced loss of clinical effects were retreated. Two had rapid improvement in clinical scores with minimal symptom expression at Week 8, which was maintained through 12 months of retreatment follow-up. The third participant experienced similar improvement in MG severity scores to their initial treatment.

Interpretation: These data support continued development of Descartes-08 in myasthenia gravis and other autoantibody-associated autoimmune disorders.

Keywords: BCMA; CAR‐T; Descartes‐08; autoimmune; myasthenia gravis.

PubMed Disclaimer

References

    1. N. E. Gilhus, “Myasthenia Gravis,” New England Journal of Medicine 375, no. 26 (2016): 2570–2581.
    1. I. K. Hart, S. Sathasivam, and T. Sharshar, “Immunosuppressive Agents for Myasthenia Gravis [Internet],” Cochrane Database of Systematic Reviews 4 (2007): CD005224, https://doi.org/10.1002/14651858.CD005224.
    1. R. Mantegazza and C. Antozzi, “From Traditional to Targeted Immunotherapy in Myasthenia Gravis: Prospects for Research [Internet],” Frontiers in Neurology 11 (2020): 981.
    1. D. Menon and V. Bril, “Pharmacotherapy of Generalized Myasthenia Gravis With Special Emphasis on Newer Biologicals,” Drugs 82, no. 8 (2022): 865–887.
    1. Y. Fujii, Y. Monden, J. Hashimoto, K. Nakahara, and Y. Kawashima, “Acetylcholine Receptor Antibody Production by Bone Marrow Cells in a Patient With Myasthenia Gravis,” Neurology 35, no. 4 (1985): 577–579.

LinkOut - more resources